Table 2.

Morphological changes by the treatment group.

Morphological characteristic	Baseline			Change at the 9-month visit					Change at the 18-month visit
	Placebo	Drug	p-value	Placebo	Drug	p-value	Adj. p-valuea	Adj. p-valueb	Placebo	Drug	p-value
LRNC volume	83	56	0.25	41.1	−1.6	0.0	0.03	0.01	58	6	0.03
LRNC volume proportion	0.1	0.0	0.24	0.0	0.0	0.0	0.02	0.00	0.0	0.0	0.03
Max LRNC area proportion	0.4	0.4	0.19	0.1	0.0	0.1	0.14	0.10	0.1	0.0	0.13
PVAT volume proportion	1.5	1.6	0.56	−0.1	0.1	0.1	0.12	0.10	−0.1	0.1	0.21
Min cap thickness	0.3	0.4	0.08	0.0	0.0	0.2	0.20	0.30	0.0	0.0	0.15
Wall volume	1,595	1,543	0.63	93	16	0.2	0.28	0.41	109	60	0.51
Max IPH area	2.8	2.3	0.68	0.1	0.6	0.6	0.64	0.76	0.7	0.8	0.90
Max wall thickness	3.1	2.7	0.17	0.1	0.0	0.6	0.67	0.84	0.2	−0.1	0.18
Max diameter stenosis	0.6	0.7	0.14	0.0	0.0	0.6	0.91	0.74	0.0	0.0	0.51
IPH volume proportion	0.0	0.0	0.69	0.0	0.0	0.7	0.76	0.82	0.0	0.0	0.74
Plaque burden by volume	1.4	1.4	0.44	0.1	0.0	0.5	0.45	0.27	0.1	0.0	0.29
CALC volume	87	117	0.36	32	9	0.3	0.47	0.52	29	17	0.63
IPH volume	10.9	8.6	0.69	3.1	3.7	0.9	0.82	0.89	6.5	4.8	0.78

^a p-value adjusted for the baseline unbalanced variable EPA.

^b p-value adjusted for FA_EPA, age, sex, diabetes, hypertension, and baseline triglycerides.